Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Dysregulation of neuronal androgen receptor signaling by divergent collaborative transcription factors in Alzheimer's disease.

Created on 15 Oct 2026

Authors

Kenichi Takayama, Yutaka Suzuki, Yuko Saito, Takashi Suzuki, Shuichi Tsutsumi, Hiroyuki Aburatani, Satoshi Inoue

Published in

iScience. Volume 29. Issue 10. Pages 117731. Oct 16, 2026. Epub Sep 22, 2026.

Abstract

The transcriptional mechanisms through which androgens and androgen receptor (AR) exert specific effects on human tissues remain elusive. Here, we demonstrated that neuronal cell-specific transcription factors (TFs) may play an important role as epigenetic modifiers that shape the AR cistrome during neuronal activity. The binding of GATA3 to specific regulatory sequences in human neuronal cell models is associated with enhanced AR-mediated transcription. AR-binding sites (ARBSs) are enriched in regions overlapping with super-enhancers (SEs) that encode critical neuronal factors. Furthermore, AR signaling in aged human male brains indicates its role in supporting neural function and declines during the progression of Alzheimer's disease (AD). The expression levels of AR-associated TFs were dysregulated during aging and AD development. Altered expression of TFs may contribute to disruption of AR signaling. Thus, collaborative TFs could contribute to the neuronal androgen response and epigenetic regulation involved in aging and the progression of dementia.

PMID:
42876597
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement